DK1933869T3 - Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom - Google Patents

Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom

Info

Publication number
DK1933869T3
DK1933869T3 DK06813945.0T DK06813945T DK1933869T3 DK 1933869 T3 DK1933869 T3 DK 1933869T3 DK 06813945 T DK06813945 T DK 06813945T DK 1933869 T3 DK1933869 T3 DK 1933869T3
Authority
DK
Denmark
Prior art keywords
inflammatory disease
antagonists
treatment
eye inflammatory
autoimmune eye
Prior art date
Application number
DK06813945.0T
Other languages
Danish (da)
English (en)
Inventor
Daniel J Cua
Robert A Kastelein
Van T Tsai
Rachel Caspi
Phyllis Silver
Dror Luger
Original Assignee
Schering Corp
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1933869(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Us Gov Health & Human Serv filed Critical Schering Corp
Application granted granted Critical
Publication of DK1933869T3 publication Critical patent/DK1933869T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06813945.0T 2005-09-01 2006-08-30 Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom DK1933869T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71379205P 2005-09-01 2005-09-01
US83731206P 2006-08-11 2006-08-11
PCT/US2006/033840 WO2007027761A2 (en) 2005-09-01 2006-08-30 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Publications (1)

Publication Number Publication Date
DK1933869T3 true DK1933869T3 (da) 2010-03-01

Family

ID=37686002

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06813945.0T DK1933869T3 (da) 2005-09-01 2006-08-30 Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom

Country Status (21)

Country Link
US (6) US20080199460A1 (enExample)
EP (3) EP2116258A1 (enExample)
JP (3) JP2009507023A (enExample)
CN (1) CN101296706B (enExample)
AT (1) ATE445415T1 (enExample)
AU (1) AU2006284841B2 (enExample)
BR (1) BRPI0615297A2 (enExample)
CA (1) CA2621086A1 (enExample)
CY (1) CY1110606T1 (enExample)
DE (1) DE602006009834D1 (enExample)
DK (1) DK1933869T3 (enExample)
ES (1) ES2333260T3 (enExample)
HR (1) HRP20100014T1 (enExample)
NO (1) NO20081574L (enExample)
NZ (2) NZ566424A (enExample)
PL (1) PL1933869T3 (enExample)
PT (1) PT1933869E (enExample)
RS (1) RS51142B (enExample)
SI (1) SI1933869T1 (enExample)
TW (2) TWI372061B (enExample)
WO (1) WO2007027761A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2631961A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
NZ579297A (en) * 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
EP2392597B1 (en) * 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
US20110212100A1 (en) * 2007-08-15 2011-09-01 Tracy Keller Methods for modulating development and expansion of il-17 expressing cells
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2242504B1 (en) * 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
CN102037017B (zh) 2008-02-21 2014-07-09 麒麟-安姆根有限公司 Il-17ra-il-17rb拮抗物及其用途
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010081091A2 (en) * 2009-01-09 2010-07-15 Schepens Eye Research Institute Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
SG174891A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2011033493A1 (en) 2009-09-21 2011-03-24 Conservatoire National des Arts et Métiers Carrier conjugates of il-23-peptides and their induced antibodies
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
US8853150B2 (en) 2010-07-29 2014-10-07 Eleven Biotherapeutics, Inc. Chimeric IL-1 receptor type I antagonists
WO2012045848A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013059644A1 (en) * 2011-10-21 2013-04-25 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
US20150307606A1 (en) * 2012-12-13 2015-10-29 Ashwin Basarkar Lyophilized spherical pellets of anti-il-23 antibodies
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2970234A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Pirin polypeptide and immune modulation
EA202090948A1 (ru) 2014-12-23 2020-11-30 4Д Фарма Рисерч Лимитед Иммуномодуляция
US10058705B2 (en) 2014-12-31 2018-08-28 Micron Devices Llc Antenna assembly
CN107407677B (zh) * 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
HK1258292A1 (zh) * 2015-09-17 2019-11-08 Amgen Inc. 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答
BR112018010089A2 (pt) 2015-11-20 2018-11-13 4D Pharma Res Ltd composições compreendendo cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
AU2017226831B2 (en) 2016-03-04 2018-10-04 4D Pharma Plc Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
EP4192502A4 (en) 2020-08-05 2024-10-09 Synthekine, Inc. Compositions and methods related to il27 receptor binding
KR20230061391A (ko) 2020-08-05 2023-05-08 신테카인, 인크. gp130 결합 분자 및 사용 방법
WO2022032042A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12 receptor synthetic cytokines and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
WO2022032022A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10 receptor binding molecules and methods of use
WO2022031870A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL27Rα BINDING MOLECULES AND METHODS OF USE
US12286482B2 (en) 2020-08-05 2025-04-29 Synthekine, Inc. IL10RB binding molecules and encoding nucleic acids
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
US20240026014A1 (en) * 2020-08-05 2024-01-25 Synthekine, Inc. Compositions and methods related to receptor pairings
CN116322754A (zh) 2020-08-05 2023-06-23 辛德凯因股份有限公司 Il10ra结合分子及使用方法
KR20240082379A (ko) * 2021-10-03 2024-06-10 시스트이뮨, 인코포레이티드 암 치료 방법 및 이의 약제학적 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
MX9707021A (es) 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
MXPA02012743A (es) 2000-06-22 2003-04-25 Amgen Inc Moleculas tipo il-17 y usos de las mismas.
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
KR101053412B1 (ko) * 2002-10-30 2011-08-01 제넨테크, 인크. Ｉｌ―１７ 생성의 억제
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
CA2525184C (en) * 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
JP2008505080A (ja) * 2004-07-01 2008-02-21 ニューヨーク ユニバーシティー ＲＯＲγｔ機能の調節のための組成物および方法
DE102005032499B4 (de) * 2004-07-13 2009-10-22 Lg Electronics Inc. Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP1827447A1 (en) * 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Pyrimidine compounds and uses thereof
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US7820168B2 (en) * 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
AR051805A1 (es) 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
CA2596509A1 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
CN103145839A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP3501537A1 (en) * 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗ｉｌ−２３抗体、組成物、方法および用途
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
NO20081574L (no) 2008-05-30
JP2011184466A (ja) 2011-09-22
NZ566424A (en) 2011-10-28
US20080199460A1 (en) 2008-08-21
JP5462838B2 (ja) 2014-04-02
EP1933869B1 (en) 2009-10-14
NZ595262A (en) 2013-03-28
SI1933869T1 (sl) 2010-02-26
TW201235050A (en) 2012-09-01
DE602006009834D1 (de) 2009-11-26
EP2322219A3 (en) 2013-06-05
HRP20100014T1 (hr) 2010-02-28
CY1110606T1 (el) 2015-04-29
TW200800259A (en) 2008-01-01
TWI372061B (en) 2012-09-11
EP1933869A2 (en) 2008-06-25
US20100111954A1 (en) 2010-05-06
CA2621086A1 (en) 2007-03-08
CN101296706A (zh) 2008-10-29
US8524230B2 (en) 2013-09-03
RS51142B (sr) 2010-10-31
PL1933869T3 (pl) 2010-06-30
WO2007027761A3 (en) 2007-05-03
EP2116258A1 (en) 2009-11-11
WO2007027761A2 (en) 2007-03-08
US20140248279A1 (en) 2014-09-04
US20130323251A1 (en) 2013-12-05
ES2333260T3 (es) 2010-02-18
AU2006284841A1 (en) 2007-03-08
JP2009507023A (ja) 2009-02-19
TWI463993B (zh) 2014-12-11
AU2006284841B2 (en) 2012-11-08
PT1933869E (pt) 2009-12-24
BRPI0615297A2 (pt) 2011-05-17
HK1119578A1 (en) 2009-03-13
EP2322219A2 (en) 2011-05-18
US20110142831A1 (en) 2011-06-16
US20100111950A1 (en) 2010-05-06
CN101296706B (zh) 2011-11-30
JP2014005285A (ja) 2014-01-16
ATE445415T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
DK1933869T3 (da) Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom
NL301089I2 (nl) imlifidase
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
DE502005011119D1 (enExample)
TW200626188A (en) Biomedical devices containing amphiphilic block copolymers
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
NO20092101L (no) Okularinnretninger og fremgangsmåter for fremstilling og anvendelse derav.
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
EP3351211C0 (en) SCLERAL PROSTHESIS TO TREAT PRESBYOPIA AND OTHER EYE DISORDERS
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
DK1220852T3 (da) Substituerede diazepaner
WO2008112325A3 (en) Treatment of autoimmune disorders
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
DK1713438T3 (da) Medicinsk sæbe
WO2006116583A3 (en) Compositions comprising a polymerized benzimidazole and a buffering agent and methods of using same
WO2007031329A3 (de) Verwendung eines kollagens xenogenen ursprungs